Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.32 |
| ▸ | SHBG | P04278 | 1/20 | 0.32 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1860460 | 0.73 | CYP19A1 (0.33) | CYP19A1SHBGNR1I3 | |
| SCHEMBL3775777 | 0.72 | SHBG (0.41) | CYP19A1SHBGNR1I3 | |
| SCHEMBL1865610 | 0.72 | CYP19A1 (0.33) | CYP19A1SHBG | |
| SCHEMBL1860492 | 0.70 | CYP19A1 (0.44) | CYP19A1SHBG | |
| SCHEMBL9264391 | 0.68 | CYP19A1 (0.35) | CYP19A1SHBG | |
| SCHEMBL10437175 | 0.68 | CYP19A1 (0.35) | CYP19A1SHBG | |
| SCHEMBL3647267 | 0.68 | AR (0.35) | CYP19A1 | |
| SCHEMBL13217275 | 0.68 | AR (0.57) | CYP19A1SHBG | |
| SCHEMBL1861033 | 0.68 | SHBG (0.34) | CYP19A1SHBGNR1I3 | |
| SCHEMBL2929841 | 0.68 | AR (0.57) | CYP19A1SHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034856-B2 | 17-(1′propenyl)-17-3′-oxidoestra-4-en-3-one derivative, use thereof, and medicament containing said derivative | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-05-19 | — | — | US | disclosed |
| US-20100317632-A1 | 17-(1'PROPENYL)-17-3'-OXIDOESTRA-4-EN-3-ONE DERIVATIVE, USE THEREOF, AND MEDICAMENT CONTAINING SAID DERIVATIVE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317632-A1 | 17-(1'PROPENYL)-17-3'-OXIDOESTRA-4-EN-3-ONE DERIVATIVE, USE THEREOF, AND MEDICAMENT CONTAINING SAID DERIVATIVE | NR5A1, CYP19A1, CYP17A1 | CYP19A1 2/4885SHBG 6/4885NR1I3 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.